FDA nominee voices support for vaccines at Senate hearing scrutinizing Trump administration efforts

WASHINGTON — President Donald Trump’s pick to lead the Food and Drug Administration voiced support for the safety of long-established vaccines at a hearing Thursday, even as senators questioned her about the White House’s efforts to upend childhood immunizations.

Heidi Overton is currently serving as a White House adviser and has worked on a series of Trump health initiatives, including an executive order last month that called for splitting up and spacing out childhood vaccinations, bucking decades-old guidelines. Overton, a physician, stood beside Trump in the Oval Office when he falsely remarked that the combined measles, mumps and rubella vaccine could be “quite lethal.”

Senate Health Committee Chairman Sen. Bill Cassidy, a physician from Louisiana, pushed Overton to reject that statement and affirm the safety of FDA-approved vaccines.

“Right now every vaccine that is on the market has been determined to be safe and effective,” including the MMR vaccine, Overton said.

Cassidy has repeatedly tried to extract commitments from Trump health nominees to uphold vaccine standards, including from Health Secretary Robert F. Kennedy Jr., only to see the Republican administration push forward with efforts undermining their use.

“Kennedy gave me guarantees, and he did not keep them,” said Cassidy, a Republican. “If the president asks you to do something that goes against those guarantees you give us today, what will you do?”

Overton said she would “follow the statutory requirements” for FDA commissioners and give Trump her best advice. Later in the hearing, Overton declined to explicitly say that Trump was wrong about the MMR vaccine’s safety.

“This committee needs to know whether you will be radically honest, whether you will use your authority to stand up for sound science and protect children’s health,” Cassidy said. He didn’t indicate whether he’d support Overton’s nomination or when he might schedule a committee vote on it.

If confirmed, Overton would inherit a raft of other controversial projects at the agency, including a safety review of the nation’s principal abortion drug and new rules that make it easier to sell flavored electronic cigarettes. Both issues were a focus for Republicans and Democrats on the panel.

The FDA approved the abortion pill mifepristone in 2000 and has repeatedly affirmed its safety while broadening access, including allowing it to be sent through the mail. But Kennedy ordered an FDA review of the drug’s safety last year, following calls from anti-abortion groups and lawmakers favoring abortion restrictions.

While working at the Trump-aligned America First Policy Institute, Overton wrote that the FDA decision to allow mail delivery of mifepristone was “dangerous to women,” referring to the practice as “chemical abortion on demand.”

In response to questions from Washington Sen. Patty Murray, Overton sidestepped her personal views on the drug, stating that it “has met the safety and efficacy determinations of the FDA.” Overton said she didn’t want to “prejudge” the FDA’s ongoing safety review of the pill.

“The FDA has said this is safe,” responded Murray, a Democrat. “We need someone in FDA to make sure this is done by science.”

Republicans on the health committee, including Cassidy, recently published a report suggesting the handful of companies that sell mifepristone may not be complying with rules for overseeing doctors who prescribe the drug.

“If I’m confirmed as commissioner I would be committed to making sure every company is following the law,” Overton told Republican Sen. Jim Banks of Indiana.

Overton’s abortion views could complicate her efforts to win over two moderate Republicans on the panel: Maine Sen. Susan Collins and Alaska Sen. Lisa Murkowski. Both have bucked their party on the issue, supporting federal access to abortion. Collins is currently locked in a tight reelection race in which abortion access is a central issue.

But Collins focused her questions Thursday on a different issue: recent FDA decisions allowing new flavored e-cigarettes onto the market. Under previous administrations, including Trump’s first term, the agency had restricted sweet vaping flavors due to their potential appeal to kids.

Overton pointed out that approval of several fruit-flavored vapes had the backing of FDA scientists, who determined the products met the standard of “appropriate for the protection of public health,” by helping adult smokers quit cigarettes.

“They believed that standard was met because so many adult smokers are using flavors preferentially,” Overton said.

To become commissioner, Overton will need a majority of votes from the 21-member health committee, followed by a positive vote from the full Senate.

Under the current administration, leading the agency has involved balancing Trump’s demands for slashing regulations — such as those for vaping products — alongside Kennedy’s interests in scrutinizing vaccines, drugs and food ingredients.

Those challenges dogged the tenure of the previous FDA head, Marty Makary, who resigned in May. Makary’s time at the agency was defined by scientific disputes, leadership changes and a string of media stories detailing low morale and internal dysfunction among staffers. The FDA has lost about 20% of its employees to layoffs, buyouts, retirements or resignations since Trump took office.

Overton studied under Makary at Johns Hopkins University, where she received a doctoral degree in clinical research after earning her medical degree at the University of New Mexico.

Like Makary, Overton has no experience running a large bureaucracy, a critical skill for steering the FDA’s 16,000 staffers spread across numerous U.S. and international locations.

In financial disclosure forms, Overton reported no investments in healthcare or food companies. That’s a stark contrast to Makary and other recent FDA nominees who have had to divest investments or cut other financial ties with companies regulated by the FDA.

Overton reported $50,000 to $100,000 in student loans.